Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Increased by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 271,152 shares of the medical equipment provider’s stock after purchasing an additional 1,606 shares during the quarter. Principal Financial Group Inc. owned 0.12% of Hologic worth $19,547,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Benson Investment Management Company Inc. bought a new position in Hologic in the 4th quarter valued at about $4,832,000. Clean Yield Group lifted its stake in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after acquiring an additional 7,266 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Hologic by 2.9% in the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares in the last quarter. Versor Investments LP acquired a new position in shares of Hologic during the third quarter valued at approximately $1,677,000. Finally, JPMorgan Chase & Co. raised its holdings in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after purchasing an additional 238,222 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HOLX shares. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Raymond James reissued an “outperform” rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Performance

Shares of HOLX stock opened at $65.01 on Tuesday. The company has a market capitalization of $14.59 billion, a price-to-earnings ratio of 20.51, a P/E/G ratio of 2.14 and a beta of 0.98. Hologic, Inc. has a 1-year low of $62.69 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock’s fifty day simple moving average is $69.76 and its 200-day simple moving average is $76.41.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.